Adalimumab (Humira), the best-selling medication globally, is not worth its current price and doesn’t work as well as 2 of its competitors, according to a new report from the Institute for Clinical and Economic Review (ICER), an independent nonprofit organization that seeks to improve healthcare value by providing comprehensive clinical and cost-effectiveness analyses of treatments, tests, and procedures.
Overall, the report concludes, targeted immune-modulating (TIM) rheumatoid arthritis (RA) drugs work better than older treatments such as methotrexate, but the prices of TIMs detracted from ICER’s cost-effectiveness rating, which is based on a quality-adjusted life-year (QALY) analysis. According to ICER, most immune modulators exceed traditional cost/QALY analysis thresholds.
To be designated as cost effective by ICER, adalimumab’s net price would need to be at a 50% to 69% discount of the list price. None of its competitors, tumor necrosis factor (TNF)-alpha or other classes, hit ICER’s benchmark for value, per ICER’s report, Targeted Immune Modulators for Rheumatoid Arthritis: Effectiveness & Value, which was released April 7, 2017.
AbbeVie, the maker of adalimumab, has taken issue with the report’s conclusions and said ICER’s methodology was flawed. Analysts say that while the report is not likely to have much of an effect on adalimumab’s sales for now, it might affect pricing decisions on forthcoming novel medications and the need for those novel medications with payers. The report could potentially also affect pricing on adalimumab’s biosimilars when they are marketed.
Humira had the highest per-QALY cost of the TNF-alpha inhibitors at $232,644; infliximab (Remicade) came in the lowest at $202,824. Tocilzumab (Actemra), an IL-6 inhibitor, had the lowest overall cost at $168,600 per-QALY cost. ICER’s report noted that based on head-to-head data on effectiveness versus adalimumab, etanercept (Enbrel) was comparable in lowering disease activity; certolizumab (Cimzia) and abatacept (Orencia) matched on a variety of measures. Tocilzumab was superior to Humira at decreasing disease activity and on one common assessment scale.
The report also included comparative analyses of 2 investigational RA drugs, baricitinib (Olumiant, JAK inhibitor) and sarilumab (Kevzara, an IL-6 inhibitor), which were superior to Humira at lowering disease activity and 2 other assessment tools.
ICER’s effectiveness analyses gave Humira a “C” rating. ICER’s endorsement for moderate certainty of incremental or better benefit generally requires that a treatment receive a B+ grade.
The report concludes that although all the TIMs evaluated substantially improved health outcomes compared with conventional disease-modifying antirheumatic drugs (DMARDs) alone, their additional cost led to cost-effectiveness estimates that were well above commonly cited thresholds for cost-effectiveness, and the discounts required to achieve these thresholds are greater than estimated current discounts from wholesale acquisition costs. Compared with the market leader adalimumab, most TIMs in combination with conventional DMARDs were more favorable (lower costs and higher QALYs), ICER said.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Biosimilar Market Development Requires Strategic Flexibility and Global Partnerships
April 29th 2025Thriving in the evolving biosimilar market demands bold collaboration, early global partnerships, and a fresh approach to development strategies to overcome uncertainty and drive future success.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.